Log in

NASDAQ:ALXNAlexion Pharmaceuticals Price Target & Analyst Ratings

$108.82
+0.35 (+0.32 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$107.77
Now: $108.82
$109.20
50-Day Range
$101.14
MA: $112.55
$119.90
52-Week Range
$72.67
Now: $108.82
$125.52
Volume1.22 million shs
Average Volume2.38 million shs
Market Capitalization$24.03 billion
P/E Ratio10.25
Dividend YieldN/A
Beta1.46

Analyst Ratings

Alexion Pharmaceuticals (NASDAQ:ALXN) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
24 Wall Street analysts have issued ratings and price targets for Alexion Pharmaceuticals in the last 12 months. Their average twelve-month price target is $143.95, suggesting that the stock has a possible upside of 32.29%. The high price target for ALXN is $180.00 and the low price target for ALXN is $110.00. There are currently 1 sell rating, 6 hold ratings, 16 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.712.762.79
Ratings Breakdown: 1 Sell Rating(s)
6 Hold Rating(s)
16 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
16 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $143.95$143.95$148.20$154.56
Price Target Upside: 32.29% upside20.06% upside96.14% upside42.28% upside

Alexion Pharmaceuticals (NASDAQ:ALXN) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Alexion Pharmaceuticals (NASDAQ:ALXN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/1/2020WedbushBoost Price TargetOutperform$120.00 ➝ $138.00Low
6/1/2020Credit Suisse GroupBoost Price TargetOutperform$142.00 ➝ $147.00Low
5/29/2020SVB LeerinkBoost Price TargetOutperform$150.00 ➝ $159.00High
5/8/2020SunTrust BanksLower Price TargetBuy$141.00 ➝ $135.00Low
5/7/2020BMO Capital MarketsLower Price TargetOutperform$147.00 ➝ $142.00Low
5/7/2020Raymond JamesLower Price TargetOutperform$159.00 ➝ $156.00Low
5/7/2020Morgan StanleyBoost Price TargetEqual Weight$116.00 ➝ $120.00Low
5/6/2020CfraLower Price TargetStrong-Buy$165.00 ➝ $159.00Medium
5/6/2020NomuraReiterated RatingBuy$133.00Medium
5/5/2020William BlairDowngradeOutperform ➝ Market PerformMedium
4/27/2020Cantor FitzgeraldInitiated CoverageNeutral$121.00High
4/20/2020UBS GroupReiterated RatingReduceHigh
4/17/2020JPMorgan Chase & Co.Lower Price TargetOverweight$168.00 ➝ $163.00High
3/17/2020OppenheimerDowngradeOutperform ➝ Market PerformHigh
3/12/2020Wolfe ResearchInitiated CoverageOutperform$140.00High
3/5/2020Bank of AmericaDowngradeBuy ➝ Neutral$130.00 ➝ $110.00Low
2/3/2020Nomura SecuritiesLower Price TargetBuy$165.00 ➝ $133.00Low
1/31/2020Robert W. BairdLower Price TargetOutperform$165.00 ➝ $140.00High
1/31/2020Royal Bank of CanadaInitiated CoverageOutperform ➝ Positive$135.00Medium
1/30/2020CowenReiterated RatingBuy$165.00High
11/17/2019Evercore ISIReiterated RatingBuy$145.00Low
9/6/2019Piper Jaffray CompaniesSet Price TargetBuy$180.00Low
8/30/2019CitigroupSet Price TargetBuy$150.00Low
8/30/2019Stifel NicolausReiterated RatingHoldLow
5/23/2019Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$142.00Low
3/21/2019GuggenheimReiterated RatingNeutral ➝ Neutral$135.00High
9/28/2018BarclaysBoost Price TargetPositive ➝ Overweight$175.00Low
7/27/2018Jefferies Financial GroupReiterated RatingHold$123.00High
3/15/2018Deutsche BankSet Price TargetBuy$161.00High
(Data available from 7/11/2018 forward)
This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.